Nice — below is a compact, sourced market reference for the Antacids Market with company references (brand owners) and available values plus the sections you asked for. I pulled recent market reports, company filings and industry lists; the most important facts are cited so you can follow up.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Antacids market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Antacids market.

Read complete report at: https://www.thebrainyinsights.com/report/antacids-market-13981

Market snapshot (consensus ranges)

• Market size / growth: estimates depend on scope (OTC antacids only vs. broader digestive OTCs). Examples: Research & Markets: USD 9.63B (2024) → USD 9.94B (2025), CAGR ≈ 3.1%;  USD 7.67B (2025) with a longer-term CAGR ~4.9%;  projects a rise from ~USD 7.44B (2024) toward ~USD 10.29B by 2034 (CAGRs vary by source). Choose the source whose scope (devices vs. services vs. OTC product mix) matches your need. 

Company references (brand owners) — values & notes

Quick note: most vendors report company- or consumer-health-segment revenue, not antacid-only revenue. Where brand-level revenue isn’t published, I list brand owner + the owner’s latest company/segment revenue so you have scale context.

1. Haleon plc — owner of TUMS & ENO (digestive brands)

   • Haleon 2024 revenue: £11.2 billion (reported full-year 2024). TUMS / ENO sit in its digestive-health portfolio; Haleon is a leading global OTC consumer-health company. 

2. Reckitt (Reckitt Benckiser) — owner of Gaviscon in many markets

   • Reckitt 2024 revenue: £14,169 million (~£14.2B) (2024 group results). Gaviscon is Reckitt’s major antacid/heartburn brand in many territories. 

3. Bayer — owner of Alka-Seltzer (antacid/effervescent)

   • Bayer 2024 sales (group): €46.6 billion (2024 annual report). Alka-Seltzer is a long-standing alkaline/effervescent antacid brand in Bayer’s OTC portfolio. Sanofi / Opella (and licensees) — Maalox / Rolaids (historical ownerships & regional licensing)

4. • Maalox historically associated with Sanofi; in the UK some Maalox products are marketed by Opella/other licensees. Rolaids was acquired by Chattem/Sanofi in prior M&A activity (brand ownership/ licensing varies by region). Use case: Sanofi / its regional licensees supply Maalox-style products. 

5. McNeil Consumer Healthcare (Kenvue) / licensees — Mylanta (brand licensing & manufacture)

   • Mylanta is currently manufactured/marketed under license arrangements by Infirst Healthcare (site notes and McNeil/Kenvue licensing historically). Kenvue (Johnson & Johnson consumer spin-out) is a major OTC player overall.

6. Other companies commonly listed in market reports (supply & private label presence): GlaxoSmithKline / Haleon, Pfizer (consumer-OTC legacy), Perrigo (store-brand/OTC manufacturing), Dr. Reddy’s, Sun Pharmaceutical, Abbott, Takeda, Bayer, Johnson & Johnson (Kenvue) — see market vendor lists for regional leaders and contract manufacturers. 

Recent developments

• Stable but modest market growth with product premiumization (combination antacids with alginates, chewable gummies and targeted digestive-health SKUs). Multiple research houses show modest CAGRs 3–5% depending on scope.

• Portfolio moves & licensing: big consumer-health groups (Haleon, Reckitt, Bayer, Sanofi/Opella) continue to reshape portfolios via divestments, licensing and targeted promotion of digestive brands. 

Drivers

• High and recurring OTC demand for heartburn/indigestion relief — convenient, low-barrier therapy for acute symptoms. 

• Product-format innovation (chewables, effervescents, flavoured formulations, alginate combinations like Gaviscon) that improve consumer experience and margins. 

• Aging populations & lifestyle factors (diet, obesity, late meals, GERD prevalence) drive sustained end-user demand. 

Restraints

• OTC competition & private-label pressure (retailers / Perrigo / contract manufacturers push lower-priced alternatives). 

• Shift to PPIs / H2 antagonists for chronic management (physicians/payers favor blockers for chronic GERD; antacids are mainly for symptomatic relief). 

• Regulatory/labels & safety in special populations (long-term antacid overuse can cause interactions or electrolyte issues), constraining some marketing claims. 

Regional segmentation analysis

• North America & Western Europe — largest markets by revenue and premium product uptake (chewables, alginate combinations). Haleon, Reckitt and Bayer are strong global suppliers. 

• Asia-Pacific — fast growth potential (urbanization, dietary changes, rising OTC penetration). Market reports flag APAC for higher CAGR vs. mature regions. 

• Latin America / MEA — smaller today but growing as OTC channels and retail penetration improve.

Emerging trends

• Combination/functional formulations (antacid + alginate or antifoaming agents; chewable and gummy formats). 

• Private-label & value SKUs growing in discount retailers — compresses branded margins but expands volume. 

• Digital / e-commerce distribution for OTC antacids (subscriptions, mental-health / GI wellness bundles). 

Top use cases

1. Acute heartburn and indigestion relief (immediate neutralization).

2. Post-meal and night-time symptomatic relief (convenience formats).

3. Adjunct to other GI therapies (short-term neutralization while awaiting acid-suppression onset).

Major challenges

• Low differentiation & commoditization — many generics / store brands compete on price.

• Shifts toward longer-term acid suppressants (PPIs/H2s) for chronic GERD limit some market expansion to short-term OTC use. 

• Regulatory variability across countries for OTC claims and ingredient limits.

Attractive opportunities

• Format innovation (gummies, effervescent, alginate-bundle SKUs) and targeted marketing to younger demographics.

• APAC premiumization — launching branded, convenient formats in fast-growing markets. 

• Private-label manufacturing & contract supply for retailers wanting store-brand antacids (higher volumes).

Key factors that will expand the market

• Product innovation lowering usage friction (fast-acting chewables, better taste, multi-benefit formats). 

• Wider e-commerce & subscription adoption for OTC medicines.

• Regional expansion into Asia & Latin America as OTC access and retail infrastructure grow. 

•  

If you’d like, I can immediately produce one of these — pick one and I’ll build it now (no wait):

1. A competitor table (CSV/Excel) listing top 12 companies, HQ, flagship antacid brands and the latest company/segment revenue figures (with citations).

2. A short 2-slide PPT summarizing market size, top brand owners (with revenue proxies) and 3 recommended go-to-market moves.

3. Pull brand-level or product-line revenues (where available) for 3 named players (e.g., Haleon — TUMS, Reckitt — Gaviscon, Bayer — Alka-Seltzer) from recent annual reports / investor presentations.

Which one should I generate now?